ECMPS-IEM
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Detection Accuracy
Conditions
Detection Accuracy, Patient Compliance
Trial Timeline
May 10, 2011 → Nov 18, 2011
NCT ID
NCT01320358About ECMPS-IEM
ECMPS-IEM is a phase 2 stage product being developed by Novartis for Detection Accuracy. The current trial status is completed. This product is registered under clinical trial identifier NCT01320358. Target conditions include Detection Accuracy, Patient Compliance.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01320358 | Phase 2 | Completed |
Competing Products
2 competing products in Detection Accuracy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tapentadol IR + Oxycodone IR | Johnson & Johnson | Pre-clinical | 23 |
| TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent | Tonix Pharmaceuticals | Phase 1 | 25 |